Improving cardiovascular health of patients with chronic kidney disease
The TRACK trial will evaluate whether a small dose of rivaroxaban, a blood-thinning medication, would reduce cardiovascular death or major cardiovascular events in patients with advanced stages of chronic kidney disease.
Twitter feed is not available at the moment.
